Free Trial

10 Best Penny Stocks to Buy Now - 9 of 10

 
 

Assertio (NASDAQ:ASRT)

Number of Upgrades from Top-Ranked Analysts
3 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$3.25 (233.4% Upside)

About Assertio

Assertio logoAssertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
7/26/2024Maxim GroupInitiated CoverageBuy$3.00
7/3/2024HC WainwrightInitiated CoverageBuy$4.00
5/28/2024Alliance Global PartnersInitiated CoverageBuy$2.75
11/3/2023BWS FinancialLower Price TargetBuy ➝ Buy$6.00 ➝ $4.00
8/4/2023BWS FinancialLower Price TargetBuy ➝ Buy$10.00 ➝ $6.00
8/4/2023Lake Street CapitalLower Price Target$9.00 ➝ $7.00
5/10/2023BWS FinancialBoost Price Target$8.00 ➝ $10.00
5/10/2023Lake Street CapitalBoost Price Target$8.00 ➝ $9.00
3/3/2023BWS FinancialBoost Price TargetBuy$6.00 ➝ $8.00
11/7/2022Lake Street CapitalInitiated CoverageBuy$7.00
 

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.